Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis

  title={Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis},
  author={Leon G D'Cruz and Kevin G. McEleney and Kyle B C Tan and Priyanka Shukla and Philip V Gardiner and Patricia Connolly and Caroline Conway and Diego F. Cobice and David S Gibson},
  journal={Journal of Personalized Medicine},
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that causes loss of joint function and significantly reduces quality of life. Plasma metabolite concentrations of disease-modifying anti-rheumatic drugs (DMARDs) can influence treatment efficacy and toxicity. This study explored the relationship between DMARD-metabolising gene variants and plasma metabolite levels in RA patients. DMARD metabolite concentrations were determined by tandem mass-spectrometry in plasma samples from… 
1 Citations

Figures and Tables from this paper

Understanding Neuromuscular Health and Disease: Advances in Genetics, Omics, and Molecular Function
The field of neuromuscular research has seen considerable recent advances in the molecular and cellular understanding of muscle biology, and the treatment of neuromuscular disease [...].


Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?
MTHFR, DHFR and ATIC genetic variants can be considered as pharmacogenetic markers of outcome in RA patients under MTX monotherapy.
Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review
A systematic review found six genetic biomarkers associated with the efficacy of MTX: ATIC rs7563206; SLC19A1 rs1051266; DHFR rs836788; TYMS rs2244500, rs2847153, and rs3786362 in at least one study and promising for predicting methotrexate efficacy.
Genetics of Rheumatoid Arthritis — A Comprehensive Review
Pharmacogenomics identified SNPs or multiple genetic signatures that may be associated with responses to traditional disease-modifying drugs and biologics.
Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.
It is demonstrated that the clinical pharmacogenetic model has an inadequate performance for the prediction of nonresponse to MTX in RA patients treated with combination therapies.
Methotrexate in Rheumatoid Arthritis
Two meta-analyses showed that methotrexate is among the most efficacious of slow-acting antirheumatic agents, together with parenteral gold (sodium aurothiomalate), penicillamine and sulfasalazine, and has one of the best efficacy/toxicity ratios.
Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy.
This review focuses on the roles of transporters involved in PK and PD with the aim of facilitating an understanding of the molecular basis of the mechanism of MTX action to achieve its effective use in RA therapy.
Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
The contribution of common genetic polymorphisms in RFC-1, ATIC, and TS (28-bp tandem repeats located in the TS enhancer region [TSER*2/*3]) and of MTXPGs to the effect ofMTX in patients with rheumatoid arthritis is investigated.
Toward a better understanding of methotrexate.
  • J. Kremer
  • Medicine
    Arthritis and rheumatism
  • 2004
Clinicians who have become familiar with the concepts presented should be better equipped to prescribe the drug in a more effective and rational manner and emerging insights into the role of naturally occurring genetic variations in cellular pathways of MTX metabolism hold promise for predicting both efficacy and toxicity of the drug.
Risk of liver disease in methotrexate treated patients
The majority of present day studies report an approximate doubling of the relative risk of elevated transaminases in methotrexate treated patients but no increased risk of symptomatic or severe liver related adverse events.
Pharmacogenomics and individualized drug therapy.
A major limitation that has heretofore moderated the use of pharmacogenetic testing in the clinical setting is the lack of prospective clinical trials demonstrating that such testing can improve the benefit/risk ratio of drug therapy.